<DOC>
	<DOCNO>NCT00600834</DOCNO>
	<brief_summary>The objective long term study prospectively compare incidence NSF two cohort ( Cohort 1- patient moderate chronic kidney disease eGFR 30-59 Cohort 2- patient severe chronic kidney disease kidney failure eGFR &lt; 30 ) .</brief_summary>
	<brief_title>Evaluation Risk NSF Following ProHance Injection Patients With Chronic Kidney Disease</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>COHORT 1 Is go receive receive PROHANCE injection MRI examination ; Has CKD eGFR stably comprise 30 59 mL/min/1.73m2 , calculate SCr value obtain local laboratory within 24 hour prior PROHANCE injection . Provides write informed consent willing comply protocol requirement . OR COHORT 2 Is go receive receive PROHANCE injection MRI examination ; Has CKD eGFR 30 mL/min/1.73m2 , calculate SCr value obtain local laboratory within 24 hour prior PROHANCE injection . Provides write informed consent willing comply protocol requirement . COHORT 1 Has receive GBCA within past 12 month prior inclusion study ; Has unstable kidney function ; Has medical condition circumstance would significantly decrease chance obtain reliable data achieve study objective ; Has ever suspect , diagnose , NSF prior studyspecific MRI ; Is unable unwilling return necessary office visit , examine dermatologist undergo deep skin biopsy development NSF suspect . OR COHORT 2 Has receive GBCA within past 12 month prior inclusion study ; Has medical condition circumstance would significantly decrease chance obtain reliable data achieve study objective ; Has ever suspect , diagnose , NSF prior studyspecific MRI ; Is unable unwilling return necessary office visit , examine dermatologist undergo deep skin biopsy development NSF suspect .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>